Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

• Status: Active, not recruiting
• Trial end date: 2022-11-01

Summary

The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary lymph nodes and their predictive value for pathologic complete response (pCR) in the breast and axilla.

And also assess 3-year invasive disease-free survival (iDFS) in patients with HER2-positive (HER: human epidermal receptor) breast cancer treated with neoadjuvant trastuzumab and pertuzumab (± endocrine therapy) using a FDG-PET response-adapted strategy.

• Phase: Phase 2

Details

• Lead Sponsor: MedSIR
• Treatments: Carboplatin; Docetaxel; Letrozole; Pertuzumab; Tamoxifen; Trastuzumab